News and Updates

Novo Nordisk removes a Catalent site from its FDA SMA drug filing to ensure regulatory success and streamline the path to market for its therapy.

Neurocrine Biosciences has launched Phase 1 trials for NBI-P'1968, a promising triple agonist targeting obesity. Learn about this new weight-loss approach.

NanoViricides receives Phase II approval for NV-387 oral gummies to treat Ebola. Learn how this innovative antiviral could reshape outbreak response.

Tenax Therapeutics’ heart failure drug, levosimendan, failed its pivotal Phase 3 trial. See the impact on PH-HFpEF treatment and the latest trial data.

WHO pushes for a Phase III trial of the Ervebo vaccine to combat the Bundibugyo Ebola outbreak. Discover the latest updates on this critical health move.

AbCellera’s ABCL635 shows promise in Phase 2 trials, significantly reducing hot flash frequency and severity with a favorable safety profile.

New Phase 2 data confirms ABCL635 significantly reduces hot flash severity and frequency, offering a promising non-hormonal breakthrough for patient care.

Veru reports Q3 fiscal results and provides a critical update on the Phase 2b PLATEAU trial for enobosarm, a candidate targeting muscle-wasting conditions.

Explore the rapid rise of radiopharmaceuticals, the clinical promise of targeted cancer therapy, and the critical safety hurdles facing this field.

China is tightening its clinical trial oversight. Explore how this shift affects global drug development and the U.S. quest for improved research speed.